IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:) \
Harbige et al.	Group Art Unit: Not yet assigned
Application No.: 10/555,757	Examiner: Not yet assigned
Filed: November 7, 2006))
For: USE OF TRIGLYCERIDE OILS CONTAINING GAMMA- LINOLENIC ACID RESIDUES AND LINOLEIC ACID RESIDUES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASE	Confirmation No.: 2532
Commissioner for Patents P.O. Box 1450 Alexandria VA 22313-1450	

DECLARATION UNDER 37 C.F.R. § 1.47 OF MR. TARIQ OSMAN

- I, TARIQ OSMAN, do hereby declare and state as follows:
- 1. I am vice president at BTG International, Ltd. ("BTG"). I have been employed at BTG for 13 years.
- 2. U.S. Application No. 10/555,757 ("the '757 application") lists Laurence S. Harbige, Michael J. Leach, Mohammed Sharief, and Paul Barraclough as inventors.

3. To the best of my knowledge, Sharief's last known work address is:

Department of Neurology Colchester General Hospital Gainsborough Wing Colchester CO4 5JL England

- 4. In an email dated September 28, 2007, to Tony Dolan of BTG (Exhibit A), I described several attempts to contact Sharief by myself, and others, to have Sharief execute a declaration for the '757 application. My three attempts are described in points 5 and 6 below.
- 5. On November 29, 2006, I called Sharief on his mobile phone and left a voicemail. I indicated that BTG would like to update him on their work regarding clinical trials and would welcome the chance to speak with him. I did not mention anything about executing the declaration for the '757 application, which I intended to bring up in our conversation if he called me back. I did not receive a response to my message.
- On June 13, 2007, I called Sharief's office, but was directed to his secretary's voicemail. I left a message and continued to try to reach him over the course of the week. On June 27, 2007, I spoke with Sharief's secretary, who indicated that she would pass my contact information on to him. I did not receive a response to my messages.
- 7. On July 25, 2007, I mailed a copy of the '757 declaration and the '757 application to Sharief at his work address and asked him to execute the declaration (Exhibit B). Exhibit C is a copy of my cover letter forwarding the

application and declaration for the '757 application for his execution. The documents were sent by United Postal Service ("UPS"). While UPS confirmed receipt by Colchester Hospital (Exhibit D), Sharief has not responded to this request for his execution of the documents.

I further declare that all statements made of my own knowledge are true and that all statements made on information and belief are believed to be true, and understand that willful false statements and the like are punishable by fine or imprisonment, or both (18 U.S.C. 1001), and may jeopardize the enforceability of any patent issuing from the '757 application.

Tariq Osman

Date

EXHIBIT A

EXHIBIT A

Tariq Osman

From: Tariq Osman

Sent: 28 September 2007 19:03

To: Tony Dolan Subject: Mo Sharief

1) Tariq Osman

Attempt 1

Called at roughly 19:24, on 29 Now 06.

I called the mobile Dr. Sharief gave me when we met last (07974109063).

Although not verbatim – I said BTG would like to move on with 0134 and take it in to clinical trials. We would like to give him an update to our work and that we would like to seek his advice on some aspects (CTA). I would welcome to hear back from him via my mobile or office phone or email and would welcome the chance to meet to discuss developments

Attempt 2 - see email below

Sent: 13 June 2007 12:20

To: Tony Dolan; Paul Mussenden; Malcolm Carter

Cc: Carol Routledge; Russell Hagan

Subject: Dr. Sharlef update

Dear all,

I ve now rang Mohammad Shareif's office a number of times.

The main switch board directs calls to Mo to his secretary Jenny. (She works from 8am to 2:30pm Monday to Friday.)

This line is constantly on voicemail – the message saying "this is Jenny – Mohammad's secretary, I'm either on the line or away from my desk and hence pis leave a recorded message and I'll get back to you."

So I ve now left a message and my number asking for Mo to contact me so we can give him a project update.

I'll keep on trying the number for the rest of the week and I'll let you know if I actually get to speak to him.

Attempt 3 - email sent Wed 27/06/2007 10:09 saying

"Just spoke to Mo's Pa - Jenny at Colchester General Hospital - Department of Neurology.

He's doing his rounds today (nearly finished his first morning round) so she will pass my contacts details and email over to Mo when he gets back into the office so he can return my call !!.

So let's wait and see if he does.

Cheers -T-"

2) Emma Spencer

Attempt 1

From: Emma Spencer Sent: 27 June 2007 10:11

To: Tariq Osman; Russell Hagan; Tony Dolan; Carol Routledge; Paul Mussenden

Subject: RE: Well - success for sorts - Mo Sharief

I just called his mobile, which was off, but I left a message – fingers crossed!

3) Paul Mussenden

Attempt 1

Jane Ensor from Howrey (lawyer representing Dr. Sharief). Jane emailed Paul (12 March 2007 18:43) saying she had emailed Dr Sharief on Saturday having picking up Pauls'email message on Friday evening. Jane email said Dr Sharief had stated that he would contact you 9Paul), but I will also forward to him your email below.

"You will appreciate that I can do nothing more than forward your message to him and it will then be his decision as to when and if he contacts you."

EXHIBIT B

604-768 143884US02 Nixon & Vanderhye P.C. (10/98). (Domestic Non-Assigned/Foreign) Page 1

RULE 63 (37 C.F.R. 1.63) INVENTORS DECLARATION FOR PATENT APPLICATION IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

As a below named inventor, I hereby declare that my residence, malling address and citizenship are as stated below next to my name, and I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

USE OF TRIGLYCERIDE OILS CONTAINING GAMMA-LINOLENIC ACID RESIDUES AND LINOLEIC ACID RESIDUES FOR THE TREATMENT

4			NEURODEGENERATIVE DISEAS	5E	
the spec	ilication of which (check	applicable box(es)):	•		
TI	s attached hereto				
[X] v	N . no belif eav	lovember 7, 2005	as U.S. Application Serial No	•	(Atty. Dkt. No. 804-756)
X X	vas filed as POT Internat	ional application No.	PCT/GB2004/002089	on 14 May 2004	
		epplication) was amende	d on '		
der ten Gat mil	1	, , , , , , , , , , , , , , , , , , , ,	•		
amendm defined i listed be which pr	ient referred to above. I a n 37 C.F.R. 1.56. I herel low and have also identif	acknowledge the duty to by claim foreign priority b led below any foreign ap	ntents of the above identified specifications to the Patent Office all intendities under 35 U.S.C. 1 19/365 of plication for patent or inventor's of the filing date of this application:	romation known to me to be of any foreign application(s) i ertificate having a filing date i	matenai to patentability as or patent or inventor's certificat
rionly r	Application Numb	er ·	Country		Day/Month/Year Filed
	0311081.4	•	United Kingdom		14 May 2003
	60/497,332		· United States		25 August 2003
	Application Numb		United States provisional applical Day/Month/Year Filed		avo or halous
I hereby	claim the benefit under 3	15 U.S.C. 120/365 of all p	vior United States and PCT Intern	national applications listed ac	love or pelow:
	S/PCT Application(*): ilon Serial No. PCT/GB2004/00200		Dzy/Month/Year Filed 14 May 2004		Status: patented pending, abandoned
					tion and halist are hallowed to
be true;	and further that these sta ment, or both, under Sec on or any natent lessed to	itements were made with tion 1001: of Title 18 of ti herenn. And on behalf o	in knowledge are true and that all the knowledge that wiliful false a ne United States Code and that si if the owner(s) hereof, I hereby ap	uch willful false statements manning North Willful false statements manning to the contract of	ey jeopardize the validity of the C., telephone number 703-816
1000 III	when all againmination	e are to be directed and	the attorneys of Custome	er Number 23117	, individually and collectively
owners/	owners' attorneys to pros patent. I also authorize communicated from the p	secute this application an	d to transact all business in the P id or delete attorneys from that C y, firm, or other organization sent	Bustomer Number, and to act	and rely solely on instructions
1.	Inventor's Signature:		4-1	Date:	
ţ 4	Inventor:	Laurence		Harbige '	British
		(first)	MI	(last)	(citizenship)
	Residence: (city)	London		e/country) <u>United Kingdom</u>	
	Mailing Address:		ondon, United Kingdom		
	(Zip Code)	E4 8EA			
2.	Inventor's Signature;	•		Date:	
Ben 6	Inventor:	Michael	V.	Leach	British
	15 to mr. 15 to 15	(first)	MI	(last)	(citizenship)
	Residence: (city)	Kent		e/country) United Kingdom	
	Malling Address:		West Wickham, Kent, United Kir	ngđom	
	(Zip Code)	BR4 9EF			
	•				•

[X] See attached sheet(s) for additional inventor(s) information!!

604-7 Serial Page	No. Unassigned					anderhye P.C. (10/ Non-Assigned/Forei	
3.	Inventor's Signature:				_ Date:		
•	Inventor:	Mohammad (lirst)	MI	Sharlef (last)		British (citizenship)	
	Residence: (city)	London	•	(state/country) United	d Kingdom		
	Malling Address:	Dept. of Clinical Neurosciences, Guy's, King's St. Thomas' School of Medicine, Hodgkin Building, Guy's Hospital, London, United Kingdom					
	(Zip Code)	SET ORT					
4.	inventor's Signature:	·			Date:		
	Inventor:	est. A	a áit	(logi)		(citizenship)	
	ma consultation.	(firet)	M	(state/country)		(curous)	
	Residence: (city)			(Signerodianty)			
	Mailing Address:						
	(Zip Code)						
	Inventor's Signature:		n		Date:		
	Inventor:	#I-A	. MI	(iast)		(citizenship)	
	Marin dalam and an Entert	((lkst)	. Mi	(state/pountry)	,	(Aurentanish)	
	Residence: (city)			(ats/a pool (i/))			
	Mailing Address: (Zip Code)						
	(Lip Code)						
6,	Inventor's Signature:				Date:		
	Inventor;						
		(first)	MI	(lest)		(citizenship)	
	Residence: (city)			(state/country)			
	Mallion Address:		•				

FOR ADDITIONAL INVENTORS, check box [] and attach sheet with same information and signature and date for each.

(Zip Code)

.

EXHIBIT C



DC: 500134

Confidential

Dr. Mohammad K. Sharief Department for Neurology Colchester General Hospital Gainsborough Wing Colchester CO4 5JL

> Tariq Osman BTG International Ltd 10 Fleet Place Limeburner Lane London EC4M 7SB

25 July 2007

Dear Mohammad,

I am sure you are as busy as ever but I hope that this letter finds you well and enjoying the work at Colchester General Hospital?

I have been trying to contact you for some time as I would like to discuss two matters with you.

The first matter relates to the developments at BTG surrounding one of your technologies. We are very happy to inform you that the BTG board agreed to fund the development of BGC20-0134 (the follow-on compound from BGC20-0884) and hence we are now quickly moving forward with the necessary preparations for a clinical trial. Currently we are finalising the IB and IMPD so that we can commence a Phase I study this coming October. Once completed and assuming the necessary end points are met, the BTG board has approved in principle further funding to take the compound into a Phase IIa study as quickly as possible.

Consequently, we would welcome the chance to appraise you face to face on this work, so we can have the opportunity to discuss with you various clinical matters surrounding the project to optimise its development as best we can. We have always appreciated the assistance and time you gave us when working on BGC20-0884, and hence we would again like to re-establish that dialogue with you to move BGC20-0134 forward.

The second matter I'd like to discuss with you is the patent assignments for the technology. To make sure we secure the best IP position for your technology we need to have these documents countersigned by you ASAP, so we can have them filed with the appropriate patent authorities. This is becoming critical as we need to make sure the patent situation is as robust as possible, so that we can continue to secure the necessary funding for this project to take it forward. The above commitment from BTG is conditional on resolving this patent administration issue. If we don't get these documents processed it will greatly reduce the chances of BTG (or anyone else) providing the financial support necessary to continue the development of this truly disease modifying technology, and to get it to the patients that need it.



To expedite matters, I've included the necessary documents that require your signature. To ease administration for you, I have included a BTG addressed envelope so you can quickly and simply return all the documents to BTG. I'd be very grateful if you could return these to me as soon as possible.

As I say we would greatly welcome the chance to meet you, to expand on the great strides BTG has made with your technology. BGC20-0134 has now become an important clinical project within BTG. We realise this would be an ideal time to reconnect with you so that we can discuss and optimise its continued development, to enable it to reach the patients you intended it for.

My contact details are below. We'd be very happy to host you at BTG, but we'd be happy to come to Colchester and discuss the work we have done to date if this would be more convenient

Very best wishes Mohammad

-Tariq-

BTG International Ltd

Mobile: 077 99 50 777 2

Email: tariq.osman@btgplc.com

Enc:

Our ref: 143884: Copy of International Application No. PCT/GB04/002089, as published Preliminary amendment as filed at the United States Patent & Trademark Office US Assignment document and Inventors Declaration document Canadian Assignment document – NB this document requires witnessing Spanish Assignment document Finnish Assignment document Swedish Assignment document

Our ref: 500134: Copy of International Application No. PCT/GB04/003524, as published Preliminary amendment as filed at the United States Patent & Trademark Office US Assignment document and Inventors Declaration document Canadian Assignment document – NB this document requires witnessing Chinese Assignment document Finnish Assignment document

Our ref: 500850: Copy of International Application No. PCT/GB05/004516, as published Appointment of agent document Preliminary amendment as filed at the United States Patent & Trademark Office US Assignment document and Inventors Declaration document

EXHIBIT D

Karen Murphy

From:

QuantumView [QuantumViewNotify@ups.com]

Sent:

26 July 2007 10:44

To:

Karen Murphy

Subject: UPS Delivery Notification, Tracking Number 1Z57A0496697487670

***Do not reply to this e-mail. UPS and BTG International Limited will not receive your reply.

At the request of BTG International Limited, this notice is to confirm that the following shipment has been delivered.

Important Delivery Information

Delivery Date / Time: 26-July-2007 / 10:12 AM

Delivery Location: Goods In

Signature Obtained

Shipment Detail

Ship To:

Colchester General Hospital Department of Neurology Gainsborough Wing Colchester Essex CO45JL GB

UPS Service:

EXPRESS

Shipment Type:

Letter

Tracking Number:

1Z57A0496697487670 Reference Number 1: 500134/500850/143884

This e-mail contains proprietary information and may be confidential. If you are not the intended recipient of this e-mail, you are hereby notified that any dissemination, distribution or copying of this message is strictly prohibited. If you received this message in error, please delete it immediately.

This e-mail was automatically generated by UPS e-mail services at the shipper's request. Any reply to this e-mail will not be received by UPS or the shipper. Please contact the shipper directly if you have questions regarding the referenced shipment or you wish to discontinue this notification service.

2IIKIIKX8AvJRO_